These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20298476)

  • 41. Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide.
    Yan T; Skaftnesmo KO; Leiss L; Sleire L; Wang J; Li X; Enger PØ
    BMC Cancer; 2011 Dec; 11():524. PubMed ID: 22185371
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Upregulation of DLX2 confers a poor prognosis in glioblastoma patients by inducing a proliferative phenotype.
    Yan ZH; Bao ZS; Yan W; Liu YW; Zhang CB; Wang HJ; Feng Y; Wang YZ; Zhang W; You G; Zhang QG; Jiang T
    Curr Mol Med; 2013 Mar; 13(3):438-45. PubMed ID: 23331016
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Platelet-derived growth factor receptor α/glial fibrillary acidic protein expressing peritumoral astrocytes associate with shorter median overall survival in glioblastoma patients.
    Leiss L; Mega A; Olsson Bontell T; Nistér M; Smits A; Corvigno S; Rahman MA; Enger PØ; Miletic H; Östman A
    Glia; 2020 May; 68(5):979-988. PubMed ID: 31769546
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cytochrome P450 1B1 expression in glial cell tumors: an immunotherapeutic target.
    Barnett JA; Urbauer DL; Murray GI; Fuller GN; Heimberger AB
    Clin Cancer Res; 2007 Jun; 13(12):3559-67. PubMed ID: 17575219
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma.
    Mineo JF; Bordron A; Baroncini M; Maurage CA; Ramirez C; Siminski RM; Berthou C; Dam Hieu P
    J Neurooncol; 2007 Dec; 85(3):281-7. PubMed ID: 17571214
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Divergent differentiation in pleomorphic xanthoastrocytoma. Evidence for a neuronal element and possible relationship to ganglion cell tumors.
    Powell SZ; Yachnis AT; Rorke LB; Rojiani AM; Eskin TA
    Am J Surg Pathol; 1996 Jan; 20(1):80-5. PubMed ID: 8540612
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The evolution of the histology in pleomorphic xanthoastrocytomas in children: a study of 15 cases.
    Wu X; Bandopadhayay P; Ng J; Ashley D; Chow CW
    Pathology; 2011 Jan; 43(1):9-16. PubMed ID: 21240059
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CD34 and microtubule-associated protein 2 expression in dysembryoplastic neuroepithelial tumours with an emphasis on dual expression in non-specific types.
    Sung CO; Suh YL; Hong SC
    Histopathology; 2011 Aug; 59(2):308-17. PubMed ID: 21884210
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic implications of the DNA damage response pathway in glioblastoma.
    Seol HJ; Yoo HY; Jin J; Joo KM; Kong DS; Yoon SJ; Yang H; Kang W; Lim DH; Park K; Kim JH; Lee JI; Nam DH
    Oncol Rep; 2011 Aug; 26(2):423-30. PubMed ID: 21617879
    [TBL] [Abstract][Full Text] [Related]  

  • 50. p53 immunohistochemical positivity as a prognostic marker in intracranial tumours.
    Soini Y; Niemelä A; Kamel D; Herva R; Bloigu R; Pääkkö P; Vähäkangas K
    APMIS; 1994 Oct; 102(10):786-92. PubMed ID: 7826609
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New variants of malignant glioneuronal tumors: a clinicopathological study of 40 cases.
    Varlet P; Soni D; Miquel C; Roux FX; Meder JF; Chneiweiss H; Daumas-Duport C
    Neurosurgery; 2004 Dec; 55(6):1377-91: discussion 1391-2. PubMed ID: 15574220
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunohistochemical study of central neurocytoma, subependymoma, and subependymal giant cell astrocytoma.
    You H; Kim YI; Im SY; Suh-Kim H; Paek SH; Park SH; Kim DG; Jung HW
    J Neurooncol; 2005 Aug; 74(1):1-8. PubMed ID: 16078101
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of blood protein biomarkers that aid in the clinical assessment of patients with malignant glioma.
    Xu BJ; An QA; Srinivasa Gowda S; Yan W; Pierce LA; Abel TW; Rush SZ; Cooper MK; Ye F; Shyr Y; Weaver KD; Thompson RC
    Int J Oncol; 2012 Jun; 40(6):1995-2003. PubMed ID: 22307528
    [TBL] [Abstract][Full Text] [Related]  

  • 54. IGF-IR: a new prognostic biomarker for human glioblastoma.
    Maris C; D'Haene N; Trépant AL; Le Mercier M; Sauvage S; Allard J; Rorive S; Demetter P; Decaestecker C; Salmon I
    Br J Cancer; 2015 Sep; 113(5):729-37. PubMed ID: 26291053
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differential expression of S100 calcium-binding proteins characterizes distinct clinical entities in both WHO grade II and III astrocytic tumours.
    Camby I; Lefranc F; Titeca G; Neuci S; Fastrez M; Dedecken L; Schäfer BW; Brotchi J; Heizmann CW; Pochet R; Salmon I; Kiss R; Decaestecker C
    Neuropathol Appl Neurobiol; 2000 Feb; 26(1):76-90. PubMed ID: 10736069
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunohistochemical localization of glial fibrillary acidic protein in human glial neoplasms.
    Velasco ME; Dahl D; Roessmann U; Gambetti P
    Cancer; 1980 Feb; 45(3):484-94. PubMed ID: 6243508
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diagnostic delay and survival in high-grade gliomas - evidence of the 'waiting time paradox'?
    Aggarwal A; Herz N; Campbell P; Arkush L; Short S; Rees J
    Br J Neurosurg; 2015; 29(4):520-3. PubMed ID: 25738427
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pleomorphic xanthoastrocytoma with a gangliomatous component: an immunohistochemical and ultrastructural study.
    Kordek R; Biernat W; Sapieja W; Alwasiak J; Liberski PP
    Acta Neuropathol; 1995; 89(2):194-7. PubMed ID: 7732793
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serum concentrations of glial fibrillary acidic protein (GFAP) do not indicate tumor recurrence in patients with glioblastoma.
    Vietheer JM; Rieger J; Wagner M; Senft C; Tichy J; Foerch C
    J Neurooncol; 2017 Oct; 135(1):193-199. PubMed ID: 28717884
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival.
    Aaberg-Jessen C; Christensen K; Offenberg H; Bartels A; Dreehsen T; Hansen S; Schrøder HD; Brünner N; Kristensen BW
    J Neurooncol; 2009 Oct; 95(1):117-128. PubMed ID: 19430729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.